Cart is empty Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukemia significantly improves patient outcomes post-transplant, reducing the risk of the life-threatening complication of graft versus host disease (GVHD).
Leave A Comment